STING1 and neoplasm: In contrast to the results obtained from mouse tumor models, these STING agonists alone did not show prominent antitumor effects in early clinical trials; nevertheless, outcomes were more promising when combined with an immune checkpoint inhibitor (NCT03010176, NCT03172936).